Characterization of 5-fluorouracil microspheres for colonic delivery

被引:81
作者
Rahman, Ziyaur
Kohli, Kanchan
Khar, Roop K.
Ali, Mushir
Charoo, Naseem A.
Shamsher, Areeg A. A.
机构
[1] Hamdard Univ, Dept Pharmaceut, New Delhi 110063, India
[2] Hamdard Univ, Dept Pharmacol, New Delhi 110063, India
关键词
5-FU; colon-specific; microspheres; alginate; Eudragit S-100; DSC; HPLC;
D O I
10.1208/pt070247
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this investigation was to prepare and evaluate the colon-specific microspheres of 5-fluorouracil for the treatment of colon cancer. Core microspheres of alginate were prepared by the modified emulsification method in liquid paraffin and by cross-linking with calcium chloride. The core microspheres were coated with Eudragit S-100 by the solvent evaporation technique to prevent drug release in the stomach and small intestine. The microspheres were characterized by shape, size, surface morphology, size distribution, incorporation efficiency, and in vitro drug release studies. The outer surfaces of the core and coated microspheres, which were spherical in shape, were rough and smooth, respectively. The size of the core microspheres ranged from 22 to 55 mu m, and the size of the coated microspheres ranged from 103 to 185 mu m. The core microspheres sustained the drug release for 10 hours. The release studies of coated microspheres were performed in a pH progression medium mimicking the conditions of the gastrointestinal tract. Release was sustained for up to 20 hours in formulations with core microspheres to a Eudragit S-100 coat ratio of 1:7, and there were no changes in the size, shape, drug content, differential scanning calorimetry thermogram, and in vitro drug release after storage at 40 degrees C/75% relative humidity for 6 months.
引用
收藏
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 1997, GUID IND DISS TEST I
[2]  
[Anonymous], 1992, PHARM RES
[3]  
CALIS S, 2002, CHITOSAN PHARM CHEM, P65
[4]  
CORTESI E, 1990, J CHEMOTHERAPY, V2, P47
[5]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[6]   CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].
DIASIO, RB ;
HARRIS, BE .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237
[7]   THERMOANALYSIS OF MICROSPHERES [J].
DUBERNET, C .
THERMOCHIMICA ACTA, 1995, 248 :259-269
[8]  
HAHN RG, 1975, CANCER, V35, P1031, DOI 10.1002/1097-0142(197504)35:4<1031::AID-CNCR2820350403>3.0.CO
[9]  
2-N
[10]   FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666